Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - The Lancet, 2012 - thelancet.com
Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …
被引用次数：692 相关文章

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

C Wong, L Jayaram, N Karalus, T Eaton… - Lancet (London …, 2012 - europepmc.org
Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - Lancet, 2012 - thelancet.com
Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - The Lancet, 2012 - infona.pl
Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory
properties. We tested the hypothesis that azithromycin would decrease the frequency of …

[引用][C] Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - The Lancet, 2012 - cir.nii.ac.jp
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE):
a randomised, double-blind, placebo-controlled trial | CiNii Research CiNii 国立情報学 …
[PDF] 91sqs.net

[PDF][PDF] Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - Lancet, 2012 - sys.91sqs.net
Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

[引用][C] Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C WONG, L JAYARAM, L STOREY… - Lancet (British …, 2012 - pascal-francis.inist.fr
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE):
a randomised, double-blind, placebo-controlled trial CNRS Inist Pascal-Francis CNRS …

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - 2012 - cabidigitallibrary.org
Background: Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - The Lancet, 2012 - Elsevier
BACKGROUND: Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

[引用][C] Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

C Wong, L Jayaram, N Karalus, T Eaton, C Tong… - The …, 2012 - Elsevier Limited